Cost of Goods Sold: The difference between beginning and ending inventories for tangible products, resulting in an expense that reflects production and sales costs.
Pfizer Inc. (PFE) had Cost of Goods Sold of $4.09B for the most recently reported fiscal quarter, ending 2026-06-30.
| Income Statement Financials | |
$15.03B |
|
$-248.00M |
|
|
Cost of Goods Sold |
$4.09B |
$10.94B |
|
$11.97B |
|
$3.06B |
|
$-3.72B |
|
$-653.00M |
|
$-653.00M |
|
$-246.00M |
|
$-246.00M |
|
$-237.00M |
|
$-246.00M |
|
$3.06B |
|
$4.69B |
|
5.70B |
|
5.70B |
|
$-0.04 |
|
$-0.04 |
|
| Balance Sheet Financials | |
$41.36B |
|
$19.03B |
|
$159.77B |
|
$201.13B |
|
$32.65B |
|
$60.49B |
|
$82.99B |
|
$115.64B |
|
$85.49B |
|
$-32.98B |
|
$85.49B |
|
5.70B |
|
| Cash Flow Statement Financials | |
$3.45B |
|
$2.89B |
|
$-6.52B |
|
$1.20B |
|
$1.03B |
|
$-164.00M |
|
$521.00M |
|
$-4.90B |
|
-- |
|
| Fundamental Metrics & Ratios | |
1.27 |
|
-- |
|
-- |
|
0.41 |
|
0.74 |
|
72.78% |
|
20.38% |
|
20.38% |
|
-- |
|
-4.34% |
|
-1.65% |
|
$2.48B |
|
-- |
|
-- |
|
-- |
|
0.07 |
|
0.41 |
|
1.20 |
|
74.77 |
|
-0.29% |
|
0.75% |
|
-0.12% |
|
-0.17% |
|
$15.00 |
|
$0.44 |
|
$0.61 |
|